Abstracts tagged "modified stoke ankylosing spondylitis spinal score (MSASSS) and x-ray"

Abstract Number: 3L • 2017 ACR/ARHP Annual Meeting
Secukinumab Demonstrates Low Radiographic Progression and Sustained Efficacy through 4 Years in Patients with Active Ankylosing Spondylitis
Jürgen Braun¹, Xenofon Baraliakos¹, Atul A. Deodhar², Denis Poddubnyy³, Paul Emery⁴, Evie Maria Delicha⁵, Zsolt Talloczy⁶ and Brian Porter⁶, ¹Rheumazentrum Ruhrgebiet, Herne, and Ruhr University Bochum, Herne, Germany, ²Division of Arthritis & Rheumatic Diseases, Oregon Health & Science University, Portland, OR, ³Department of Rheumatology, Charité Universitätsmedizin Berlin, Berlin, Germany, ⁴Leeds Musculoskeletal Biomedical Research Unit/Institute Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom, ⁵Novartis Pharma AG, Basel, Switzerland, ⁶Novartis Pharmaceuticals Corporation, East Hanover, NJ

Background/Purpose: Secukinumab, a fully human anti–interleukin-17A monoclonal antibody, reported improved signs and symptoms of ankylosing spondylitis (AS) in the MEASURE 1 trial.1 Here, we report…
Abstract Number: 1526 • 2017 ACR/ARHP Annual Meeting
Shift Analysis of Spinal Radiographic Progression after 2 Years of Secukinumab in Ankylosing Spondylitis – Detailed Results from a Phase 3 Trial
Xenofon Baraliakos¹, Jürgen Braun¹, Albert Widmer², Ayan Das Gupta³, Aimee Readie⁴, Brian Porter⁴ and Corine Gaillez², ¹Rheumazentrum Ruhrgebiet, Herne, Germany, ²Novartis Pharma AG, Basel, Switzerland, ³Novartis Healthcare Pvt. Ltd, Hyderabad, India, ⁴Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background/Purpose: An overall low rate of spinal radiographic progression with the modified Stoke Ankylosing Spondylitis Spinal Score (mSASSS) was reported with secukinumab (SEC), a fully…
Abstract Number: 6L • 2015 ACR/ARHP Annual Meeting
Effect of Interleukin-17A Inhibition on Spinal Radiographic Changes through 2 Years in Patients with Active Ankylosing Spondylitis: Results of a Phase 3 Study with Secukinumab
Xenofon Baraliakos¹, Atul A. Deodhar², Jürgen Braun¹, Dominique Baeten³, Maxime Dougados⁴, Joachim Sieper⁵, Paul Emery⁶, Aimee Readie⁷, Ruvie Martin⁷, Shephard Mpofu⁸ and Hanno Richards⁸, ¹Rheumazentrum Ruhrgebiet, Herne, Germany, ²Division of Arthritis & Rheumatic Diseases, Oregon Health & Science University, Portland, OR, ³Clinical Immunology and Rheumatology, Academic Medical Center, Amsterdam, Netherlands, ⁴Hospital Cochin, Descartes Univ, Paris, France, ⁵University Hospital Charité, Berlin, Germany, ⁶NIHR-Leeds Musculoskeletal Biomedical Research Unit, University of Leeds, Leeds, United Kingdom, ⁷Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁸Novartis Pharma AG, Basel, Switzerland
Background/Purpose: In the MEASURE 1 trial (NCT01358175), secukinumab significantly improved the signs and symptoms of patients (pts) with active ankylosing spondylitis (AS) over 52 weeks…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].